Genetic Risk Factor for Premature Birth Found
|
By LabMedica International staff writers Posted on 22 May 2014 |

Image: The iQ5 real-time polymerase chain reaction (PCR) detection system (Photo courtesy of Bio-Rad).
A genetic risk factor for premature birth has been discovered and it is related to a gene that codes for a protein that the scientists have found helps the body’s immune cells recognize and fight group B streptococcal (GBS) bacteria.
These GBS bacteria also known as Streptococcus agalactiae, are found in the vagina or lower gastrointestinal tract of approximately 15% to 20% of healthy women, but may cause life-threatening infections, such as sepsis or meningitis in newborns, especially those born prematurely.
Scientists at University of California, San Diego (La Jolla, CA, USA) and their international collaborators, studied a pair of proteins that together helps balance the body’s immune response to pathogens, by directing some antimicrobial response without provoking excessive inflammation. They isolated neutrophils from whole blood from three to six different donors per genotype. Freshly isolated sterile human placentas obtained from caesarian section were used for preparation of amniotic epithelial membranes (AM).
The investigators performed gene expression analysis, cytokine secretion, and cell signaling studies. Real-time polymerase chain reaction (PCR) was performed on an iQ5 machine (Bio-Rad Laboratories; Hercules, CA, USA) and cytokines in culture supernatants were quantitated using enzyme-linked immunosorbent assay (ELISA) kits (R&D Systems; Minneapolis, MN, USA). Paraffin sections were deparaffinized, blocked for endogenous nonspecific sites, and stained with human anti-sialic acid-binding immunoglobulin-like lectin 5 (Siglec-5) and anti–Siglec-14 antibodies.
The team found that the protein Siglec-5 binds to the GBS pathogen and suppresses immune response to the microbe, while the other protein, Siglec-14, binds to the pathogen, and activates killing of the bacteria. These sialic acid-binding immunoglobulin-type lectins are cell surface receptors found typically on immune cells. They recognize and bind sialic acids, which are sugar molecules that densely coat cells. The gene for Siglec-14 is missing in some individuals, and the investigators have found that fetuses that lack the Siglec-14 protein are at higher risk of premature birth, likely due to an imbalanced immune response to the bacterial infection.
Victor Nizet, MD, professor of pediatrics and pharmacy and coauthor of the study said, “Pregnant women are universally screened for these bacteria during pregnancy and administered antibiotics intravenously during labor if they test positive to protect the infant from infection. Our study may explain why some women and their infants are at higher risk of acquiring severe GBS infections than others.” The study was published on May 5, 2014, in the Journal of Experimental Medicine.
Related Links:
University of California, San Diego
Bio-Rad Laboratories
R&D Systems
These GBS bacteria also known as Streptococcus agalactiae, are found in the vagina or lower gastrointestinal tract of approximately 15% to 20% of healthy women, but may cause life-threatening infections, such as sepsis or meningitis in newborns, especially those born prematurely.
Scientists at University of California, San Diego (La Jolla, CA, USA) and their international collaborators, studied a pair of proteins that together helps balance the body’s immune response to pathogens, by directing some antimicrobial response without provoking excessive inflammation. They isolated neutrophils from whole blood from three to six different donors per genotype. Freshly isolated sterile human placentas obtained from caesarian section were used for preparation of amniotic epithelial membranes (AM).
The investigators performed gene expression analysis, cytokine secretion, and cell signaling studies. Real-time polymerase chain reaction (PCR) was performed on an iQ5 machine (Bio-Rad Laboratories; Hercules, CA, USA) and cytokines in culture supernatants were quantitated using enzyme-linked immunosorbent assay (ELISA) kits (R&D Systems; Minneapolis, MN, USA). Paraffin sections were deparaffinized, blocked for endogenous nonspecific sites, and stained with human anti-sialic acid-binding immunoglobulin-like lectin 5 (Siglec-5) and anti–Siglec-14 antibodies.
The team found that the protein Siglec-5 binds to the GBS pathogen and suppresses immune response to the microbe, while the other protein, Siglec-14, binds to the pathogen, and activates killing of the bacteria. These sialic acid-binding immunoglobulin-type lectins are cell surface receptors found typically on immune cells. They recognize and bind sialic acids, which are sugar molecules that densely coat cells. The gene for Siglec-14 is missing in some individuals, and the investigators have found that fetuses that lack the Siglec-14 protein are at higher risk of premature birth, likely due to an imbalanced immune response to the bacterial infection.
Victor Nizet, MD, professor of pediatrics and pharmacy and coauthor of the study said, “Pregnant women are universally screened for these bacteria during pregnancy and administered antibiotics intravenously during labor if they test positive to protect the infant from infection. Our study may explain why some women and their infants are at higher risk of acquiring severe GBS infections than others.” The study was published on May 5, 2014, in the Journal of Experimental Medicine.
Related Links:
University of California, San Diego
Bio-Rad Laboratories
R&D Systems
Latest Molecular Diagnostics News
- Self-Collected HPV Testing Reaches Patients Missed by Routine Screening
- Genetic Risk Score Identifies Type 1 Diabetes in MODY Testing
- Comprehensive Genomic Testing Expands Treatment Options for Advanced Cancers
- Multi-Omics Analysis Identifies Additional Risk Genes in Hereditary Breast and Ovarian Cancer
- Blood Test for Lung Cancer Screening Receives FDA Breakthrough Device Designation
- Machine Learning Approach Expands Epigenetic Testing for Prenatal Genetic Disorders
- New Liquid Biopsy Workflow Maximizes Tumor Signals from Limited Blood Samples
- Sequencing-Based Newborn Screening Identifies Pediatric Cancer Risk at Birth
- Liquid Biopsy Combines Multiple Signals for Cancer Detection in a Single Analysis
- Newborn Screening Program Adds Spinal Muscular Atrophy Testing Across England
- Blood Test Could Help Fast-Track Lymphoma Diagnosis in Resource-Limited Settings
- Liquid Biopsy Assay Enriches Tumor DNA for Early Detection and Monitoring
- Whole-Cell Genomic Analysis Expands the Potential of Liquid Biopsy
- Point-of-Care Multiplex PCR Test Submitted to FDA for Flu A/B and RSV Detection
- New PCR Assays Expand Cyclospora Testing for Outbreak Surveillance
- Single Liquid Biopsy Predicts Early Immunotherapy Benefit in Advanced Lung Cancer
Channels
Clinical Chemistry
view channel
Rapid Ferritin Test Enables Iron Deficiency Detection at the Point of Care
Iron deficiency is one of the world’s most common nutritional disorders and can be difficult to diagnose where access to laboratories and trained personnel is limited. Women and children in low-resource... Read more
Alzheimer’s Blood Test Becomes First FDA-Cleared Option for Adults as Young as 40
C2N Diagnostics’ PrecivityAD2 blood test was cleared by the U.S. Food and Drug Administration (FDA) on August 20, 2026, for adults as young as 40 who are experiencing signs of cognitive impairment, according... Read moreHematology
view channel
New Genetic Findings Reveal Cause of Bone Marrow Failure Syndrome
Inherited bone marrow failure syndromes (IBMFS) impair the bone marrow’s ability to produce sufficient healthy blood cells and are associated with an increased risk of early-onset myelodysplastic syndromes (MDS).... Read more
Ultra-Portable Device Enables Finger-Prick Blood Testing at Home
Patients who need frequent blood tests often face repeated clinic visits that burden services and disrupt care. In the UK, millions of tests are performed each year to diagnose disease, guide therapy,... Read moreImmunology
view channel
Immune Biomarkers May Predict Recurrent Checkpoint Inhibitor Arthritis
Inflammatory arthritis is a recognized immune-related adverse event in patients treated with immune checkpoint inhibitors (ICIs) for cancer. Between 20% and 50% of affected patients experience more than... Read more
Immune Cell Blood Test May Predict Melanoma Immunotherapy Response
Melanoma remains one of the deadliest skin cancers, although outcomes improve markedly when the disease is detected early. Immunotherapy has extended survival for many patients with advanced melanoma,... Read moreMicrobiology
view channel
Genetic Marker Identifies Emerging Resistance to Frontline Malaria Drugs
Artemisinin-based combination therapy remains central to controlling Plasmodium falciparum malaria, but emerging drug resistance is complicating treatment and surveillance. In Uganda and across sub-Saharan... Read more
Surveillance and Susceptibility Testing Track Rising Candida Auris in U.S.
Drug-resistant fungal infections are straining infection control and treatment in hospitals and long-term care facilities, where rapid transmission can lead to severe outcomes. Candida auris has expanded... Read morePathology
view channel
Simple Immunohistochemical Size Ratio Improves Classification of Primary Aldosteronism
Primary aldosteronism is a common but underdiagnosed cause of hypertension, in which excess aldosterone promotes salt retention and raises blood pressure. Identifying the dominant source of hormone overproduction... Read more
30-Minute 3D Histology Tool Supports Intraoperative Glioma Margin Assessment
Glioma surgery depends on distinguishing infiltrative tumor from functional brain tissue, but microscopic spread beyond visible margins makes this difficult. Conventional frozen sections provide rapid... Read moreTechnology
view channel
Autonomous Robotic System Receives FDA Authorization for Blood Collection
Venipuncture is central to many diagnostic pathways, but routine blood collection can be affected by staffing constraints and procedural variability that influence consistency and patient experience.... Read more
Interoperable Data Platform Standardizes Multi-Cancer Blood Test Results
Proteotype Diagnostics has introduced Alchemi, a proprietary data and clinical workflow platform being developed for Enlighten, the company’s investigational blood-based multi-cancer test.... Read moreIndustry
view channel
AI-Powered Pathology Collaboration Supports Companion Diagnostic Development
Imagene AI has joined the Proscia Ready partner alliance to integrate its hematoxylin and eosin (H&E) screening tools and immunohistochemistry (IHC) image-analysis capabilities with Proscia’s Concentriq... Read more







